Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia

Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillinger, Genevra, Abdul-Aziz, Amina, Zaitseva, Lyubov, Lawes, Matthew, MacEwan, David J., Bowles, Kristian M., Rushworth, Stuart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544001/
https://www.ncbi.nlm.nih.gov/pubmed/26292723
http://dx.doi.org/10.1038/srep12949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544001/
https://www.ncbi.nlm.nih.gov/pubmed/26292723
http://dx.doi.org/10.1038/srep12949

Ejemplares similares